Open Access. Powered by Scholars. Published by Universities.®
- Discipline
- Publication
- Publication Type
Articles 1 - 4 of 4
Full-Text Articles in Medicine and Health Sciences
Analysis Of Anti-Xa Concentrations In Patients On Treatment Dose Enoxaparin: A Retrospective Chart Review, Lauren Levine, Nicole Pallme, Erik Angelotti, Dane L. Shiltz
Analysis Of Anti-Xa Concentrations In Patients On Treatment Dose Enoxaparin: A Retrospective Chart Review, Lauren Levine, Nicole Pallme, Erik Angelotti, Dane L. Shiltz
Dane L. Shiltz
The purpose of this retrospective chart review was to determine the correlation between full weight-based enoxaparin use and the frequency of anti-Xa concentrations within the defined therapeutic range; to ascertain if anti-Xa monitoring is being appropriately ordered in relation to the timing of enoxaparin dose (after 3 consistent therapeutic doses and 3-5 hours post-dose); to establish if the evidence-based recommended dose adjustment protocol that was studied in the pediatric population was utilized; and if this yielded anti-Xa concentrations within the target range (0.6 – 1.1 IU/mL) for an adult population. The data may suggest a lack of correlation between BMI …
Correlation Of Treatment Dose Enoxaparin With Anti-Xa Concentrations In Adult Hemodialysis Inpatients, Paul E. Brumley, Miroslav A. Anguelov, Jason P. Hecht, Dane L. Shiltz
Correlation Of Treatment Dose Enoxaparin With Anti-Xa Concentrations In Adult Hemodialysis Inpatients, Paul E. Brumley, Miroslav A. Anguelov, Jason P. Hecht, Dane L. Shiltz
Dane L. Shiltz
Enoxaparin, a low-molecular-weight-heparin, is being used in hemodialysis patients despite a lack of guideline or manufacturer dose recommendations. Due to enoxaparin’s renal excretion, the possibility of accumulating anti-Xa concentrations in hemodialysis patients using enoxaparin creates a hemorrhagic risk, calling for more research. The objectives of this study are to determine the correlation between treatment dose enoxaparin use and anti-Xa concentrations within the defined therapeutic range in patients receiving chronic, scheduled hemodialysis to determine the degree of change in anti-Xa concentrations in those cases where a concentration was obtained before and after a specific hemodialysis session, and to determine if there …
A Comparative Study Between Fondaparinux, A Low-Molecular-Weight Heparin, And Recombinant Hirudin In Thromboembolic Prophylaxis After Major Abdominal Surgery In The Surgical Intensive Care Unit, Ezzeldin S. Ibrahim, Hager H. Mohammady, Hatem A. Atalla, Magda F. Yehyia, Sadek A. Sadek
A Comparative Study Between Fondaparinux, A Low-Molecular-Weight Heparin, And Recombinant Hirudin In Thromboembolic Prophylaxis After Major Abdominal Surgery In The Surgical Intensive Care Unit, Ezzeldin S. Ibrahim, Hager H. Mohammady, Hatem A. Atalla, Magda F. Yehyia, Sadek A. Sadek
Menoufia Medical Journal
Objective Evaluation of the safety and the efficacy of different anticoagulants in thromboembolic prophylaxis after major abdominal surgeries. Background Thromboembolic events are serious complications after major abdominal surgeries, and there are different modalities to prevent them. Materials and methods Sixty patients who underwent major abdominal surgery were assigned in a randomized, double-blinded manner and classified into three groups: group A (n = 20) was started on enoxaparin at a daily dose of 40 mg. Group B (n = 20) was given recombinant hirudin 15 mg twice daily. Group C (n = 20) was given fondaparinux 2.5 mg …
Correlation Of Treatment Dose Enoxaparin With Anti-Xa Concentrations In Adult Hemodialysis Inpatients, Paul E. Brumley, Miroslav A. Anguelov, Jason P. Hecht, Dane L. Shiltz
Correlation Of Treatment Dose Enoxaparin With Anti-Xa Concentrations In Adult Hemodialysis Inpatients, Paul E. Brumley, Miroslav A. Anguelov, Jason P. Hecht, Dane L. Shiltz
Scholarship and Professional Work – COPHS
Enoxaparin, a low-molecular-weight-heparin, is being used in hemodialysis patients despite a lack of guideline or manufacturer dose recommendations. Due to enoxaparin’s renal excretion, the possibility of accumulating anti-Xa concentrations in hemodialysis patients using enoxaparin creates a hemorrhagic risk, calling for more research. The objectives of this study are to determine the correlation between treatment dose enoxaparin use and anti-Xa concentrations within the defined therapeutic range in patients receiving chronic, scheduled hemodialysis to determine the degree of change in anti-Xa concentrations in those cases where a concentration was obtained before and after a specific hemodialysis session, and to determine if there …